Cantor Fitzgerald raised the firm’s price target on Disc Medicine (IRON) to $153 from $132 and keeps an Overweight rating on the shares. Disc Medicine announced it was one of the initial recipients of FDA Commissioner’s National Priority Voucher for bitopertin in erythropoietic protoporphyria, the analyst tells investors in a research note. A key advantage is that there is a higher likelihood of approval, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine Receives FDA Priority Voucher for Bitopertin
- Disc Medicine price target raised to $108 from $89 at Raymond James
- 3 Best Stocks to Buy Now, 10/17/2025, According to Top Analysts
- Disc Medicine price target raised to $110 from $90 at Wedbush
- Promising Outlook for Disc Medicine: Buy Rating Backed by FDA Priority Voucher and Strategic Preparations for Bitopertin Launch